Oncocyte (IMDX) Competitors

Oncocyte has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Prothena has a beta of -0.33, suggesting that its share price is 133% less volatile than the broader market.

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oncocyte has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Oncocyte presently has a consensus target price of $10.50, suggesting a potential upside of 150.00%. Prothena has a consensus target price of $24.57, suggesting a potential upside of 175.16%. Given Prothena's stronger consensus rating and higher probable upside, analysts clearly believe Prothena is more favorable than Oncocyte.

Prothena has a net margin of -80.68% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Prothena's return on equity.

In the previous week, Prothena had 1 more articles in the media than Oncocyte. MarketBeat recorded 2 mentions for Prothena and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.89 beat Prothena's score of 0.93 indicating that Oncocyte is being referred to more favorably in the media.

Oncocyte has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

Oncocyte has higher revenue and earnings than Kyverna Therapeutics. Oncocyte is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Oncocyte. MarketBeat recorded 2 mentions for Kyverna Therapeutics and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.89 beat Kyverna Therapeutics' score of 1.61 indicating that Oncocyte is being referred to more favorably in the media.

Kyverna Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Oncocyte currently has a consensus price target of $10.50, suggesting a potential upside of 150.00%. Kyverna Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 313.22%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than Oncocyte.

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Editas Medicine had 11 more articles in the media than Oncocyte. MarketBeat recorded 12 mentions for Editas Medicine and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.89 beat Editas Medicine's score of 0.80 indicating that Oncocyte is being referred to more favorably in the news media.

Editas Medicine has a net margin of -157.32% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Editas Medicine's return on equity.

Editas Medicine has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

Editas Medicine presently has a consensus target price of $6.00, suggesting a potential upside of 122.22%. Oncocyte has a consensus target price of $10.50, suggesting a potential upside of 150.00%. Given Oncocyte's higher probable upside, analysts clearly believe Oncocyte is more favorable than Editas Medicine.

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Oncocyte has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

In the previous week, Puma Biotechnology had 4 more articles in the media than Oncocyte. MarketBeat recorded 5 mentions for Puma Biotechnology and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.89 beat Puma Biotechnology's score of 0.87 indicating that Oncocyte is being referred to more favorably in the news media.

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by insiders. Comparatively, 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Puma Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Puma Biotechnology has a net margin of 11.50% compared to Oncocyte's net margin of -2,955.63%. Puma Biotechnology's return on equity of 20.76% beat Oncocyte's return on equity.

Puma Biotechnology has higher revenue and earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Puma Biotechnology presently has a consensus price target of $6.00, suggesting a potential downside of 34.21%. Oncocyte has a consensus price target of $10.50, suggesting a potential upside of 150.00%. Given Oncocyte's stronger consensus rating and higher probable upside, analysts plainly believe Oncocyte is more favorable than Puma Biotechnology.